Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Management of AIDS-Related Kaposi’s Sarcoma

  • Susan E. Krown
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_12-1


Kaposi’s sarcoma (KS) (Overview: Aids-Related and Non-aids-Related Cancers; Cancers Related to HIV) is a multifocal angiogenic neoplasm whose development requires systemic infection with a human herpesvirus, known as human herpesvirus-8 (HHV-8) or the KS-associated herpesvirus (KSHV) (Kaposi’s Sarcoma-Associated Herpesvirus). KSHV infection is required for the development of this neoplasm, but KS occurs in only a fraction of KSHV-infected individuals. Although KS lesions may arise in the absence of overt immunodeficiency, defects in endogenous viral control mechanisms increase the likelihood that KS will develop (Epidemiology of AIDS-Related Malignancies). KS is thus more frequently observed among individuals with underlying conditions, such as HIV infection, which impair antiviral immune responses, and is considered an AIDS-defining condition when it occurs in an HIV-infected person. In formulating a management strategy for KS in HIV-infected individuals, two main aspects...


Immune Reconstitution Inflammatory Syndrome KSHV Infection Recombinant Interferon Alfa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Gwanzura L, Schooley RT, Campbell TB. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis. 2010;51:342–9.PubMedCrossRefGoogle Scholar
  2. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS. 1999;13:2105–11.PubMedCrossRefGoogle Scholar
  3. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116:3969–77.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother. 2011;55:2696–703.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Housri N, Yarchoan R, Kaushal A. Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary? Cancer. 2010;116:273–83.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2005;23:982–9.PubMedCrossRefGoogle Scholar
  7. Krown SE. AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? Cytokine Growth Factor Rev. 2007;18:395–402.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Krown SE. Kaposi's sarcoma. Chapter 59. In: Dolin R, Masur H, Saag MS, editors. AIDS therapy. 3rd ed. London: Churchill Livingstone Elsevier; 2008. p. 1011–29.Google Scholar
  9. Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. 1989;7:1201–7.Google Scholar
  10. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15:3085–92.PubMedGoogle Scholar
  11. Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, Venkatarmanan R, Han K, Cesarman E, Dittmer DP. Rapamycin with antiretroviral therapy in AIDS-Associated Kaposi Sarcoma: an AIDS Malignancy Consortium Study. J Acquired Immune Def Syndr. 2012;59:447–54.CrossRefGoogle Scholar
  12. Letang E, Naniche D, Bower M, Miro JM. Kaposi sarcoma-associated immune reconstitution inflammatory syndrome: in need of a specific case definition. Clin Infect Dis. 2012;55:157–8.PubMedCrossRefGoogle Scholar
  13. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012;60:150–7.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART Era – the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003;21:2876–82.PubMedCrossRefGoogle Scholar
  15. O'Donnell PJ, Pantanowitz L, Grayson W. Unique histologic variants of cutaneous Kaposi sarcoma. Am J Dermatopathol. 2010;32:244–50.PubMedGoogle Scholar
  16. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12:905–12.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Stebbing J, Portsmouth S, Gazzard B. How does HAART lead to the resolution of Kaposi's sarcoma? J Antimicrob Chemother. 2003;51:1095–8.PubMedCrossRefGoogle Scholar
  18. Yarchoan R, Pluda JM, Wyvill KM, Aleman K, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Little RF. Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit Rev Immunol. 2007;27:401–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.AIDS Malignancy ConsortiumNew YorkUSA